期刊文献+

晚期上皮性卵巢癌患者“间歇性肿瘤细胞减灭术”手术适应证的探讨 被引量:11

A discussion about indications of interval debulking surgery in patients with advanced epithelial ovarian cancer
下载PDF
导出
摘要 目的:探讨间歇性肿瘤细胞减灭术(IDS)的适应证。方法:采用回顾性病例对照研究,分析2000年1月至2009年12月间71例初次肿瘤细胞减灭术不满意的ⅢC~Ⅳ期卵巢上皮癌(包括原发性腹膜癌,原发性输卵管癌)患者的资料。A组(n=41)初次减灭术后单纯化疗6~8疗程;B组(n=30)经3~4个疗程化疗后行间歇性肿瘤细胞减灭术,然后继续化疗4~6疗程。化疗方案均为铂类为基础的联合化疗。两组患者的化疗方案和疗程无差异。通过比较两组患者的临床特征、手术及生存情况,以及B组患者IDS术前CA125、B超检查与术后病理结果的对应关系,总结IDS的适应证。结果:B组30例患者中23例(76.7%)最终达到满意减瘤,共有11例术后病理结果为阴性,术前CA125或B超对病理结果阳性预测的敏感度差,CA125的特异性达100%。CA125联合B超的预测准确率为70%。A、B组的五年生存率(P=0.790)、OS(P=0.254)和PFS(P=0.289)均无显著性差异。B组中无肉眼残留病灶患者的PFS和OS较A组有明显延长的趋势。结论:间歇性肿瘤细胞减灭术主要适应证是:初次肿瘤细胞减灭术采用"基本术式",3个疗程化疗后部分缓解,CA125仍异常;或CA125恢复正常,最好经PET-CT或增强CT明确有残留病灶。残留病灶有可能通过再次手术切除干净,达到无肉眼残留,这部分患者有可能生存获益。 Objective:To study and discuss indications of interval debulking surgery(IDS) undergone by patients with advanced epithelial ovarian cancer(EOC).Methods:71 consecutive patients with stage ⅢC and Ⅳ EOC(including primary peritoneal carcinoma or primary fallopian tube carcinoma) who underwent suboptimal primary debulking surgery and platinum-based chemotherapy were enrolled from Jan.2000 to Dec.2009.They were divided into 2 groups:group A consists of 41 patients who received 6 to 8 courses of platinum-based chemotherapy after suboptimal PDS.Group B was made by the other 30 patients who received IDS following suboptimal PDS.Indications of IDS was discussed by comparing all patients'clinical characteristics,perioperative situation and prognosis.It was also necessary to check the CA125 level and B ultrasound both before and after IDS in group B,then compared them with pathological consequence.Results:23 patients(76.7%,23/30) from group B had gone through optimal debulking,among which there were 11 who got a negative pathological result.The sensitivity of both CA125 level and B ultrasound before IDS were poor,while the specificity of CA125 level could reach to 100%.The accuracy of CA125 combined with B ultrasound to predict pathological consequence is 70%.The five-year survival rate(P=0.790),OS(P=0.254),PFS(P=0.289) were close for both groups.For those who got no gross residual in group B seem to have a longer PFS and OS than those in group A.Conclusions:The major indications of IDS are concluded as follows:(1) basic dubulking in PDS;(2) partial remission after 3 courses of chemotherapy with abnormal CA125 level;(3) normal CA125 with positive consequence in PET-CT/E-CT;(4) residual lesion could be removed in further IDS.
出处 《现代妇产科进展》 CSCD 2012年第7期505-508,共4页 Progress in Obstetrics and Gynecology
关键词 晚期卵巢上皮性癌 间歇性肿瘤细胞减灭术 手术 适应证 Advanced epithelial ovarian cancer Interval debulking surgery Surgery indications
  • 相关文献

参考文献10

  • 1Robert J,Morgan J, Ronald D. NCCN clincal practice guide- lines in oncology, Ovarian Cancer, including fallopian tube tumor and primary peritoneal cancer[ Z] .2011.
  • 2崔恒,李艺.卵巢癌初始治疗中手术相关若干问题及临床意义[J].国际妇产科学杂志,2011,38(4):285-288. 被引量:6
  • 3Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 pa- tients [ J ]. Gynecol Oncol, 1998,71 ( 3 ) :431-436.
  • 4Everett EN, French AE, Stone RL,et al. Initial chemother- apy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer [ J]. Am J Obstet Gynecol,2006,195 (2) :568-576.
  • 5Hegazy MA, Hegazi RA, Elshafei MA, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma[ J]. World J Surg Oncol,2005,3 ( 1 ) :57-64.
  • 6Lee SJ, Kim BG, Lee JW,et al. Preliminary results of neo- adjuvant chemotherapy with paclitaxel and cisplatin in pa- tients with advanced epithelial ovarian cancer who are in- adequate for optimum primary surgery [ J ]. J Obstet Gynaecol Res ,2006,32( 1 ) :99-106.
  • 7Inciura A, Simavicius A, Juozaityte E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the manage- ment of advanced ovarian cancer : a retrospective study of 574 patients [ J ]. BMC Cancer,2006,8 (6) : 153.
  • 8Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gyneco- logic oncologists treating advanced epithelial ovarian cancer? [ J ]. Gynecol Oncol,2001,82 (3) :489-497.
  • 9van der Burg ME,van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gyneco- logical Cancer Cooperative Group of tire European Organi- zation for Research and Treatment of Cancer[ J ]. N Engl J Med, 1995,332(10) :629-634.
  • 10Rose PG, Nerenstone S, Brady MF, et al. Secondary sur- gical cytoreduction for advanced ovarian carcinoma[ J ]. N Engl J Med,2004,351 (24) :2489-2497.

二级参考文献14

  • 1Chan JK, Cheung MK, Husain A, et al. Patterns and progress in o- varian eaneer over 14 years [J]. Obstet Gyneeol,2006,108 (3 pt 1 ) : 521-528.
  • 2NCCN clincal practice guidelines in oncology,ovarian cancer, including fallopian tube tumor and primary peritoneal cancer. 2011.
  • 3Vergote I, van Gorp T, Amant F ,et al. Timing of debulking surgery in advanced ovarian cancer [J]. Int J Gynecol Cancer,2008, (18 Suppl 1 ) : 11-19.
  • 4Chen SS,Lee L. Incidence of paraaortic and pelvic lymph node metastasis in epithelial ovarian cancer [J]. Gynecol Oncol, 1983,16:95.
  • 5Bristow RE ,Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis [J]. J Clin Oncol,2002,20(5) : 1248-1259.
  • 6Hegazy MA,Hegazi RA, Elshafei MA,et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma [J]. World J Surg Oncol,2005,3:57.
  • 7Lee S J, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and eisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery [J ]. J Obstet Gynaecol Res, 2006,32( 1 ) :99-106.
  • 8Everett EN ,French AE, Stone RL, et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage Ⅲ/Ⅳ epithelial ovarian cancer[J ]. Am J Obstet Gynecol, 2006,195 (2) :568-576.
  • 9Ineiura A, Simavieius A, Juozaityte E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients [J]. BMC Cancer, 2006,6:153.
  • 10Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer [ J ]. Gynecol Oncol, 2000,78 (3 pt 1 ) : 269-274.

共引文献5

同被引文献110

  • 1吴鸣,沈铿,郎景和,黄荣丽,黄惠芳,潘凌亚.Ⅲ期卵巢上皮性癌临床和预后因素分析[J].中华医学杂志,2005,85(20):1406-1409. 被引量:16
  • 2谢幸.卵巢癌新辅助化疗[J].中国妇产科临床杂志,2006,7(4):243-244. 被引量:9
  • 3Ivanov S, Batashki I. Five years survival in patients with endometri- oid ovarian cancer versus patients with serous ovarian cancer. Akush Ginekol (Sofiia) . 2008.47 ( 5 ) :9 - 11.
  • 4谢敏,李艺,崔恒.复发性卵巢癌的手术治疗,2012,28(5):330-334.
  • 5李艺,张芸娜,马或,等.原发性卵巢粘液性癌的临床特征分析,2012,21(2):89-93.
  • 6Bell J, Brady MF, Young RC, et al . Randomized phase 11I trial of three versus six cycles of adjuvant carbopatin and paclitaxel in early stage epithelial ovarian carcinoma : a Gynecologic Oncology Group study . Gynecol Oncol ,2006,102 ( 3 ) :432 - 439.
  • 7Walker JI. Intraperitoneal chemotherapy for ovariancancer: 2009goals [ J ]. Gynecol 0nco|,2009,112 (03) :439-440.
  • 8Fotopoulou C, Savatis K. Primary radical surgery in elderly patient ' s with epithelial ovarian cancer analysis of surgical outcome and long-term survival [ J ]. Int J Gynecol Cancer, 2010,20 ( 1 ) : 34- 40.
  • 9Tracey EA, Roder DM. Reasons for improved survival from ovarian cancer in New South Wales, Australia, Between1980and2003: Implications for Cancer Control [ J. Gynecol Cancer, 2009, 19 (4) :591-599.
  • 10Chang S J, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreduc- tire surgical procedures on survival in advanced ovarian cancer [ J]. Ann Surg Oncol,2012,19:4059-4067.

引证文献11

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部